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NEWS RELEASE

July 2, 1990
CATS HELP UM RESEARCHER STALK AIDS ANSWERS
BY KRISTIN RODINE
UM NEWS AND PUBLICATIONS
In the fight against AIDS, cats may hold the key.

And

University of Montana scientist Tom North hopes to use that key to
unlock the puzzle of how to cure, or at least curtail, the deadly
virus.
North, an associate professor of biological sciences, is
conducting a federally funded study to find an effective way to fight
AIDS through antiviral drugs.

His goal is to identify a drug or

drugs that can stop AIDS in cats, assuming that what works on the
feline virus will have an identical impact on its human counterpart.
Acquired Immune Deficiency Syndrome, declared "Public Health
Enemy Number One" by President Ronald Reagan, is incurable,
invariably fatal and spreading through the population at an alarming
pace.

Scientists throughout the world are struggling to change that

grim picture, and North thinks he has found an ideal means toward
that end.
Feline Immunodeficiency Virus (FIV), which causes the immunesystem breakdown in cats, is nearly identical in makeup and symptoms
to its human counterpart, HIV, North says.

Cats spread the disease

among themselves by fighting and biting, he adds, but people cannot

more

CatAids.rl

2

catch the feline disease.

So FIV is like HIV in many ways that

benefit researchers, but not in the way that endangers them.
"We're very fortunate that the feline AIDS virus is so similar
to the human AIDS virus in the disease it causes and in the drugs you
use to treat it," North says.

"And i t ’s safe to work with in the lab

... I couldn't really think of anything that I could have done to
make it a better model."
The similarity of the feline and human viruses works in both
species' favor.

Just as progress toward an HIV breakthrough can be

hastened by using an animal model, the urgency of finding a cure for
human AIDS gives a big boost to feline virus research.

The potential

benefit to human patients makes FIV a high-priority research topic,
qualifying for grant funds that would not be available if the work
would only benefit animals, North says.
The prospect of helping to stop a modern plague makes North's
work extremely exciting, he says.

And Peggy Johnston of the National

Institute of Allergy and Infectious Diseases (NIAID), which is
funding North’s research, says his FIV work shows "a lot of promise."
If North fully develops FIV as a reliable model for testing AIDS
drugs on animals, that would provide "one of the things that has
really been lacking and that has hindered our progress in finding new
therapies for AIDS," says Johnston, chief of the developmental
therapeutics branch of the NIAID's AIDS division.
"Tom is one of the few people in the country who is ... geared
toward development of a model for drug evaluation," she
more

says. "He
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has considerable history with antiviral drugs and antiviral
metabolism and, I think, is in a unique position to combine his past
expertise with this particular model.”
North was recruited into the AIDS battle by the NIAID because of
his successful antiviral work on herpes viruses.

He was among a

relatively small group of scientists who developed a way to suppress
herpes symptoms with drugs, laying the groundwork for all subsequent
antiviral research.
Before that herpes breakthrough, North says, it was generally
believed that chemotherapy would not work on viruses, tiny particles
that grow by infiltrating the cells of the organisms they infect.
"Because most of the metabolism it uses is the cell’s metabolism,” he
says, "it was thought that anything you would do to inhibit virus
replication would kill the cell.”
Now herpes can be controlled safely with drugs that hit the
virus without damaging the host cell, North says, adding, "Our
challenge now is to do that for AIDS and then ... for other viruses."
North’s strategy for fighting AIDS centers on an enzyme, reverse
transcriptase, that is crucial to the viral replication process in
both FIV and HIV.
"When the virus infects a human cell ... the very first step in
this process is carried out by this enzyme,” North says.

"So the

rationale here is that if you inhibit this enzyme, you prevent
everything that the virus can do.”
North is in the second year of a three-year, approximately
more
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$360,000 NIAID grant to study FIV as a model for AIDS chemotherapy.
He feels confident that funding will be extended, and ’’within five
years we should know whether these approaches will work."

Another

likely source of funding is North’s collaboration with Burroughs
Wellcome, manufacturer of the widely used AIDS drug AZT.

He hopes to

expand his anti-AIDS efforts considerably this fall with the help of
an anticipated grant from Burroughs Wellcome.
The work in North's lab is strictly "in vitro," using cell
cultures, not animals.

He works closely with scientists at the

University of California at Davis who do "in vivo" research with
laboratory animals.
Antiviral research is currently the hot prospect in the fight
against AIDS, North says, although early hopes focused on finding a
vaccine.
While chemotherapy fights the virus after it has infected a
patient, he says, a vaccine would be the ideal weapon against AIDS
because it would prevent infection, teaching the immune system to
kill the virus on contact.

But for a vaccine to work, the immune

system has to recognize the exterior of the virus, and the AIDS virus
changes so quickly that "an immune response that recognizes one
(strain of the virus) won't work against the others," he says.
"It's the same problem we have with cold viruses.

That's why

there's no vaccine for colds."
North's antiviral approach attacks an interior part of the
virus, the enzyme reverse transcriptase, which remains the same in
more
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all variations of the virus, he says.

So it presents a stable target

for anti-AIDS medication.
Even if a vaccine were developed, North adds, work toward an
effective antiviral drug would still be essential because a vaccine
couldn’t help the millions who have already been infected by HIV.
North was the first scientist to study FIV as a model for AIDS
antiviral work and, in June 1989, he was the first to publish a paper
on the topic.

Since then, he says, the feline model has gained broad

acceptance, attracting other scientists to FIV work.
He believes FIV research stands a good chance of producing an
AIDS breakthrough, making it a disease people can live with even if
an absolute cure cannot be found.
"Ultimately what we would like to do is develop something that
would eliminate the virus," North says.
possible.

"I d o n ’t know if that's

But I would be willing to at least initially settle for a

treatment (like the herpes drugs), something that would suppress the
virus replication enough so that as long as the patient takes the
drug they don't have any problems.
"I'd call that a cure."
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